At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 9, 2026 at 17:15 ET
Lisata Therapeutics held its 2026 annual meeting on November 9, 2026. Stockholders approved the 2026 Equity Incentive Plan (44,764,472 initial shares plus annual evergreen increases) and the 2026 Employee Stock Purchase Plan (3,730,372 initial shares). The meeting was adjourned solely on Proposal No. 3 (conversion of Series C Convertible Preferred Stock, which would represent >20% of outstanding shares and result in a change of control) to allow more time for proxy solicitation and Nasdaq listing application approval; the reconvened meeting is set for November 30, 2026.
- Stockholders approved the 2026 Equity Incentive Plan with an initial reserve of 44,764,472 shares plus annual evergreen increases of 5% of outstanding shares.
- Stockholders approved the 2026 Employee Stock Purchase Plan with an initial reserve of 3,730,372 shares plus annual evergreen increases through 2036.
- The annual meeting was adjourned solely on Proposal No. 3 (conversion of Series C Non-Voting Convertible Preferred Stock) to allow more time for proxy solicitation and Nasdaq listing application approval.
- The reconvened meeting on Proposal No. 3 is scheduled for November 30, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access